Welcome to our dedicated page for Ocuphire Pharma news (Ticker: OCUP), a resource for investors and traders seeking the latest updates and insights on Ocuphire Pharma stock.
Ocuphire Pharma reports developments for a clinical-stage ophthalmic biopharmaceutical business focused on small-molecule therapies for retinal and refractive eye disorders. Recurring news covers APX3330, an oral Ref-1 inhibitor in development for diabetic retinopathy, and Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist designed to reduce pupil size.
Company updates also address ophthalmology clinical trial data, RYZUMVI for pharmacologically induced mydriasis through a commercial partner, presbyopia and dim-light vision disturbance programs, scientific meeting presentations, financial results, capital-structure matters, shareholder votes, and governance disclosures.
Ocuphire Pharma, a clinical-stage ophthalmic biopharmaceutical company, announced that its CEO Mina Sooch and other executives will participate in a fireside chat on December 14, 2020, at 11am ET, hosted by Kristen Kluska of Cantor Fitzgerald. The discussion will cover 2021 data catalysts, late-stage trial designs for Nyxol and APX3330, and competitive landscapes for four ophthalmic indications. Ocuphire's pipeline includes Nyxol, entering Phase 3 trials, and APX3330, entering Phase 2 trials. Research on Ocuphire has been initiated by Cantor Fitzgerald.
Ocuphire Pharma (NASDAQ: OCUP) has initiated patient enrollment for the MIRA-2 Phase 3 trial, evaluating Nyxol® for reversing pharmacologically-induced mydriasis. The trial aims to enroll 168 patients across 12 clinical sites in the U.S., with top-line results expected by Q1 2021. Previous research indicates a strong market demand for such a drug, as 45% of surveyed patients expressed interest in a reversal drop. The MIRA-1 Phase 2b study has been accepted for publication in the journal Optometry and Vision Science.
Ocuphire Pharma has achieved notable milestones with its lead candidates, Nyxol and APX3330. The Japanese Patent Office has approved a patent for Nyxol, covering its use in daily administration until 2034. Additionally, Ocuphire received a $1.7 million NIH grant for research on APX3330, which is advancing into Phase 2 trials targeting diabetic retinopathy and diabetic macular edema. These developments indicate potential growth in their ophthalmic portfolio, enhancing market positioning and partnerships in Asia and Europe.
Ocuphire Pharma has published two significant papers on its drug candidate APX3330, highlighting its potential in treating inflammatory and angiogenic diseases. These publications, featured in Drug Discovery Today and Inflammatory Bowel Disease, indicate that Ref-1 inhibition may benefit conditions like diabetic retinopathy and chronic colitis. A Phase 2 trial, ZETA-1, is set to begin in early 2021, evaluating APX3330's efficacy in diabetic retinopathy with an enrollment goal of 100 patients. The drug aims to demonstrate improvements in retinal health and anti-inflammatory properties.
Ocuphire Pharma will participate in the H.C. Wainwright 6th Annual Israel Conference on November 12, 2020, at 3:30 PM. This follows their recent merger with Rexahn Pharmaceuticals and a private placement closure. Ocuphire, trading under the ticker symbol OCUP on Nasdaq, focuses on developing therapies for eye disorders. Their lead product, Nyxol® Eye Drops, targets conditions such as night vision disturbances, while the second candidate, APX3330, is aimed at retinal diseases.
Ocuphire Pharma, a clinical-stage biopharmaceutical company, announced the appointment of Susan Benton to its board of directors, effective November 5, 2020. Benton brings over 30 years of experience in life sciences, particularly in ophthalmology, with leadership roles at notable firms such as Thea Pharma and Shire. Ocuphire has also completed merger and financing transactions, marking its trading debut on the Nasdaq under the symbol OCUP. The company focuses on therapies for eye disorders, with key products including Nyxol® Eye Drops and APX3330.
Ocuphire Pharma has completed its merger with Rexahn Pharmaceuticals, transitioning to a publicly traded biopharmaceutical entity focused on ophthalmic drug development. Starting November 6, 2020, shares will trade under the symbol 'OCUP' on the Nasdaq after a 1-for-4 reverse stock split. The merger includes a $21.15 million private placement led by institutional investors, granting them approximately 86.6% ownership of the combined firm. Ocuphire aims to advance its late-stage clinical pipeline, including products targeting various eye disorders.